Cart
sales@molnova.com
Gefapixant citrate
CAS No. 2310299-91-1
Gefapixant citrate( —— )
Catalog No. M35748 CAS No. 2310299-91-1
Gefapixant citrate is an orally active P2X3 receptor (P2X3R) antagonist that acts on human homologous recombinant hP2X3 (IC50: ~30 nM) and hP2X2/3 (IC50: 100-200 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 55 | Get Quote |
|
| 50MG | 219 | Get Quote |
|
| 100MG | 385 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameGefapixant citrate
-
NoteResearch use only, not for human use.
-
Brief DescriptionGefapixant citrate is an orally active P2X3 receptor (P2X3R) antagonist that acts on human homologous recombinant hP2X3 (IC50: ~30 nM) and hP2X2/3 (IC50: 100-200 nM).
-
DescriptionGefapixant citrate is an orally active and potent purinergic P2X3 receptor (P2X3R) antagonist, with IC50 values of ~30 nM versus recombinant hP2X3 homotrimers and 100-250 nM at hP2X2/3 heterotrimeric receptors. Gefapixant citrate can be used for the research of chronic cough and knee osteoarthritis.
-
In VitroGefapixant citrate displays no inhibitory impact on any non-P2X3 subunit containing receptors (IC50 values >10,000 nM at recombinant homotrimeric hP2X1, hP2X2, hP2X4, rP2X5 and hP2X7 channels).
-
In VivoGefapixant citrate (7d bid, orally) attenuates the weight bearing laterality with complete reversal of apparent hyperalgesia at the two higher doses in a rat model of knee osteoarthritis (14d following intra-articular administration of monoiodoacetate).
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2310299-91-1
-
Formula Weight545.52
-
Molecular FormulaC20H27N5O11S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESOC(=O)CC(O)(CC(O)=O)C(O)=O.COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Anthony P. Ford, et al. The therapeutic promise of ATP antagonism at P2X3 receptors in respiratory and urological disorders. Front Cell Neurosci. 2013; 7: 267.?
molnova catalog
related products
-
Cimicifugoside H1
Cimicifugoside H1 shows the protective function to cerebral neuron during cerebral ischemia.
-
Isoflurane
Isoflurane is a stable, non-explosive inhalation anesthetic that has been reported to induce caspase-3 activation.
-
Dasatinib carbaldehy...
Dasatinib carbaldehyde (PROTAC ABL binding moiety 4) is based on Dasatinib which is an ABL inhibitor, binds to the IAP ligand via a linker, and forms SNIPER .
